Search

Your search keyword '"Lucas Moritz Wiggenhauser"' showing total 3 results
Start Over Author "Lucas Moritz Wiggenhauser"
3 results on '"Lucas Moritz Wiggenhauser"'

1. Vascular risk profile and changes of arterial hypertension after surgical revascularization in adult Moyamoya patients

Author

Patrick Haas, Lucas Moritz Wiggenhauser, Jonas Tellermann, Helene Hurth, Daniel Feucht, Marcos Tatagiba, Nadia Khan, and Constantin Roder

Subjects
Cerebral revascularization, Moyamoya, Arterial hypertension, Medicine, Science
Abstract

Abstract Moyamoya disease (MMD) is a rare stenoocclusive cerebral vasculopathy often treated by neurosurgical revascularization using extracranial-intracranial bypasses to prevent ischemic or hemorrhagic events. Little is known about the vascular risk profile of adult MMD patients compared to the general population. We therefore analyzed 133 adult MMD patients and compared them with data from more than 22,000 patients from the German Health Update database. Patients with MMD showed an age- and sex-adjusted increased prevalence of arterial hypertension, especially in women between 30 and 44 years and in patients of both sexes between 45 and 64 years. Diabetes mellitus was diagnosed significantly more frequently in MMD patients with increasing age, whereas the vascular risk profile in terms of obesity, nicotine and alcohol consumption was similar to that of the general population. Antihypertensive medication was changed one year after surgical revascularization in 67.5% of patients with a tendency towards dose reduction in 43.2% of all patients. After revascularization, physicians need to be aware of a high likelihood of changes in arterial hypertension and should adjust all other modifiable systemic vascular risk factors to achieve the best treatment possible.

Published
2024
Full Text
View/download PDF

2. Thoracic bilateral sympathectomy attenuates oxidative stress and prevents ventricular remodelling in experimental pulmonary hypertension

Author

Raphael dos Santos Coutinho e Silva, Lucas Moritz Wiggenhauser, Rafael Simas, Fernando Luiz Zanoni, Geisla Medeiros, Fernanda Beatriz da Silva, Daniel Cury Ogata, Ana Cristina Breithaupt-Faloppa, Guido Krenning, Luiz Felipe Pinho Moreira, Groningen Institute for Organ Transplantation (GIOT), and Cardiovascular Centre (CVC)

Subjects
Male, Pulmonary and Respiratory Medicine, Pulmonary Arterial Hypertension, Ventricular Remodeling, Hypertension, Pulmonary, Ventricular Dysfunction, Right, General Medicine, Pulmonary Artery, Vascular Remodeling, Rats, Disease Models, Animal, Oxidative Stress, Ventricular Function, Right, Animals, Humans, Familial Primary Pulmonary Hypertension, Surgery, Rats, Wistar, Sympathectomy, Cardiology and Cardiovascular Medicine
Abstract

OBJECTIVES Pulmonary arterial hypertension (PAH) is a cardiopulmonary disease that affects the pulmonary vasculature, leading to increased afterload and eventually right ventricular (RV) remodelling and failure. Bilateral sympathectomy (BS) has shown promising results in dampening cardiac remodelling and dysfunction in several heart failure models. In the present study, we investigated whether BS reduces pulmonary arterial remodelling and mitigates RV remodelling and failure. METHODS PAH was induced in male Wistar rats by intraperitoneal injection of monocrotaline. Rats were divided into 3 groups, involving untreated PAH (n = 15), BS-treated PAH (n = 13) and non-manipulated control rats (n = 13). Three weeks after PAH induction, the rats were anaesthetized and RV function was assessed via the pressure-volume loop catheter approach. Upon completion of the experiment, the lungs and heart were harvested for further analyses. RESULTS BS was found to prevent pulmonary artery remodelling, with a clear reduction in α-smooth muscle actin and endothelin-1 expression. RV end-systolic pressure was reduced in the BS group, and preload recruitable stroke work was preserved. BS, therefore, mitigated RV remodelling and cardiomyocyte hypertrophy and diminished oxidative stress. CONCLUSIONS We showed that thoracic BS may be an important treatment option for PAH patients. Blockade of the sympathetic pathway can prevent pulmonary remodelling and protect the RV from oxidative stress, myocardial remodelling and function decay.

Published
2021

3. Chromanol compounds for treatment of heart failure

Author

Robert Henning, Adrianus Cornelis van der Graaf, Guido Krenning, Lucas Moritz Wiggenhauser, Groningen Institute for Organ Transplantation (GIOT), Groningen Kidney Center (GKC), and Cardiovascular Centre (CVC)

Abstract

The invention relates to certain chromanol, quinone or hydroquinone compounds and derivatives thereof for treatment of heart failure with reduced ejection fraction (HFrEF). Specifically, the present invention relates to chromanol compounds chosen from S-(6-hydroxy-2,5,7,8-tetramethylchroman-2yl)(piperazin-1-yl)methanone and S-(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(4-(2-hydroxyethyl)piperazin-1-yl)methanone, and pharmaceutically acceptable salts thereof.

Catalog

Books, media, physical & digital resources
See catalog results